Drug Discovery AI

Tech bio company combining biological large language models, multimodal patient data, and agentic software. The Owkin K co pilot has two environments: K Navigator, an agentic research environment free to academic researchers that accelerates literature review across 26.5 million articles and 19 biomedical databases and explores spatial multiomic patient data, and K Pro, an enterprise co pilot that uses a single orchestrator to select and combine specialized biological AI skills across drug discovery and development. Both are powered by Owkin Zero, a fine tuned biological reasoning model. The company reports K Pro accelerating internal drug target identification from more than 12 months to roughly 3 months, validated through collaborations with AstraZeneca, Bristol Myers Squibb, and Sanofi, including a three year AstraZeneca licensing agreement to build biopharma agents. Owkin operates a group of entities spanning a biology foundation model (Bioptimus), diagnostics (Waiv), and a clinical stage drug program (Epkin); this record covers the software platform. Founded 2016 by Thomas Clozel, MD and Gilles Wainrib, PhD.

AI foundation models for molecular design, licensed as software to pharmaceutical and life sciences R&D organizations. The models predict and reprogram interactions between biochemical molecules: Chai-1 (2024) for structure prediction, Chai-2 (2025) for fully de novo antibody design, and Chai-3 (2026), which the company describes as roughly doubling the success rate of its predecessor. On Chai-2, the company reports designing all complementarity determining regions from a target and epitope prompt alone, with hit rates reported between roughly 16 and 20 percent depending on the source, against sub 0.1 percent rates the company attributes to prior methods; validation covered approximately 50 antibody targets with fewer than 20 designs tested per target. Models are reported in production at Eli Lilly, Pfizer, and Novartis, with a collaboration announced with argenx. Unlike vendors that use AI to build their own drug pipeline, Chai's product is the model itself, including custom versions trained on a customer's proprietary data.

Generative AI drug discovery company (HKEX: 3696) operating both as a platform vendor and a clinical stage biotech. Pharma.AI comprises PandaOmics (AI target identification and indication prioritization), Chemistry42 (generative molecular design using generative tensorial reinforcement learning rather than library screening), and inClinico (clinical trial outcome prediction). The platform's flagship validation is rentosertib, a TNIK inhibitor for idiopathic pulmonary fibrosis where AI selected the target, generated the molecule, and informed trial design: it entered a 320 patient Phase III trial in July 2026, with discovery published in Nature Biotechnology and Phase IIa results in Nature Medicine. The vendor reports reaching preclinical candidate nomination in 12 to 18 months on average against a 2.5 to 4 year industry norm, and 13 programs cleared for IND.